Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | DRD3 | P35462 | 2/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.41 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.41 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19001329 | 0.87 | ALDH1A1 (0.48) | ALDH1A1KDM4ERAB9ADRD2DRD3 | |
| SCHEMBL6043717 | 0.87 | ALDH1A1 (0.48) | ALDH1A1KDM4ERAB9ADRD2DRD3 | |
| SCHEMBL18997635 | 0.84 | FAAH (0.50) | ALDH1A1KDM4ERAB9ADRD2DRD3 | |
| SCHEMBL19002634 | 0.84 | GNAI3 (0.52) | ALDH1A1KDM4EDRD2DRD3ITGB3 | |
| SCHEMBL19049361 | 0.83 | KDM4E (0.45) | ALDH1A1KDM4ERAB9ADRD2DRD3 | |
| SCHEMBL19049588 | 0.82 | ALDH1A1 (0.44) | ALDH1A1KDM4ERAB9ADRD2DRD3 | |
| SCHEMBL21169303 | 0.81 | ALDH1A1 (0.44) | ALDH1A1KDM4ERAB9ADRD2DRD3 | |
| SCHEMBL19001332 | 0.81 | KDM4E (0.43) | ALDH1A1KDM4ERAB9ADRD2DRD3 | |
| SCHEMBL19049366 | 0.79 | FAAH (0.49) | ALDH1A1KDM4ERAB9ADRD2DRD3 | |
| SCHEMBL9030108 | 0.79 | NPC1 (0.38) | ALDH1A1KDM4ENPC1KMT2ANAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060089355-A1 | Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides | ELAN PHARMACEUTICALS, INC. | 2006-04-27 | — | — | US | disclosed |
| US-5641778-A | EXHIBIT RENIN-INHIBITING PROPERTIES AND CAN BE USED AS ANTIHYPERTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089355-A1 | Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides | APP, BACE1, BACE2 | ALDH1A1 1039/4885KDM4E 1951/4885RAB9A 2414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.